The invention relates generally to a medical device, and more particularly to a medicament delivery device, and/or a simulated medicament delivery device having an electronic circuit system.
Exposure to certain substances, such as, for example, peanuts, shellfish, bee venom, certain drugs, toxins, and the like, can cause allergic reactions in some individuals. Such allergic reactions can, at times, lead to anaphylactic shock, which can cause a sharp drop in blood pressure, hives, and/or severe airway constriction. Accordingly, responding rapidly to mitigate the effects from such exposures can prevent injury and/or death. For example, in certain situations, an injection of epinephrine (i.e., adrenaline) can provide substantial and/or complete relief from the allergic reaction. In other situations, for example, an injection of an antidote to a toxin can greatly reduce and/or eliminate the harm potentially caused by the exposure. Because emergency medical facilities may not be available when an individual is suffering from an allergic reaction, some individuals carry a medicament delivery device, such as, for example, an auto-injector, to rapidly self-administer a medicament in response to an allergic reaction.
To actuate such a medicament delivery device, however, the user may be required to execute a series of operations. For example, to actuate some known auto-injectors, the user must remove a protective cap, remove a locking device, place the auto-injector in a proper position against the body and then press a button to actuate the auto-injector. Failure to complete these operations properly can result in an incomplete injection and/or injection into an undesired location of the body. In certain instances, for example, users who have become confused in the operation of some known auto-injectors have inadvertently injected the medicament into their thumb by improperly positioning the auto-injector.
The likelihood of improper use of known medicament delivery devices can be compounded by the nature of the user and/or the circumstances under which such devices are used. For example, many users are not trained medical professionals and may have never been trained in the operation of such devices. Moreover, in certain situations, the user may not be the patient, and may therefore have no experience with the medicament delivery device. Similarly, because some known medicament delivery devices are configured to be used relatively infrequently in response to an allergic reaction or the like, even those users familiar with the device and/or who have been trained may not be well practiced at operating the device. Finally, such devices are often used during an emergency situation, during which even experienced and/or trained users may be subject to confusion, panic, and/or the physiological effects of the condition requiring treatment.
Some known medicament delivery devices include printed instructions to inform the user of the steps required to properly deliver the medicament. Such printed instructions, however, can be inadequate for the class of users and/or the situations described above. Moreover, because some known medicament delivery devices, such as, for example, auto-injectors, pen injectors, inhalers or the like, can be compact, such printed instructions may be too small to read and comprehend during an emergency situation.
Some known medicament delivery devices are associated with simulated medicament delivery devices (e.g., “trainers”) to provide a method for users to practice using the medicament delivery device without being exposed to the medicament and/or needles typically contained therein. Such simulated medicament delivery devices, however, can also include inadequate use instructions as described above.
Monitoring the patient's compliance with known medicament delivery devices can also be problematic. For example, some known medicament delivery systems include a medicament delivery device and an electronic system to assist the user in setting the proper dosage and/or maintaining a compliance log. Such known medicament delivery systems and the accompanying electronic systems can be large and therefore not conveniently carried by the user. Such known medicament delivery systems and the accompanying electronic systems can also be complicated to use and/or expensive to manufacture. Moreover, some known medicament delivery systems include sensors disposed within the medicament delivery path, which can interfere with the delivery, result in contamination, or the like.
Thus, a need exists for medicament delivery systems and/or devices that provide instructions that can be easily understood by a user in any type of situation. Additionally, a need exists for simulated medicament delivery systems and/or devices that can provide instructions and that can be reused multiple times. Moreover, a need exists for medicament delivery systems and/or devices that can provide compliance information associated with the use of the device and/or that can communicate electronically with other communications devices.
Medicament delivery devices are described herein. In some embodiments, an apparatus includes a medical injector and an electronic circuit system. The medical injector includes a housing, a medicament container, and a medicament delivery member. The housing defines a first region and a second region. The first region includes the medicament container and is physically isolated from the second region. The electronic circuit system is configured to be disposed within the second region defined by the housing. The electronic circuit system is configured to output an electronic output associated with a use of the medical injector.
In some embodiments, an apparatus includes a medical injector and an electronic circuit system. The medical injector includes a housing, a medicament container, and a medicament delivery member. The housing defines a first region and a second region. The first region includes the medicament container and is physically isolated from the second region. The electronic circuit system is configured to be disposed within the second region defined by the housing. The electronic circuit system is configured to output an electronic output associated with a use of the medical injector.
In some embodiments, an apparatus includes a medical injector and an electronic circuit system. The medical injector includes a housing, a medicament container, and a medicament delivery member. The medicament delivery member can be, for example, a needle or an injection nozzle. The housing defines a first region and a second region. The first region includes the medicament container and is physically isolated from the second region. The electronic circuit system is configured to be disposed within the second region defined by the housing. The electronic circuit system includes a printed circuit board having a substrate and an electrical conductor disposed on the substrate. The substrate of the printed circuit board is configured to receive an actuator configured to disrupt the electrical conductor. The actuator can be, for example, an actuator configured to initiate delivery of a medicament from the medical injector. The electronic circuit system is configured to output an electronic output associated with a use of the medical injector when the electrical conductor is disrupted. In some embodiments, the electronic output can be, for example, associated with recorded speech.
In some embodiments, an apparatus includes a medicament delivery device and an electronic circuit. The medicament delivery device, which can be, for example, a pen injector, an auto-injector, an inhaler or a transdermal delivery device, includes a housing, a medicament container, and a medicament delivery member. The medicament container and at least a portion of the medicament delivery member are disposed within the housing. The medicament container and the medicament delivery member define a medicament delivery path. The electronic circuit system is coupled to the housing and is physically isolated from the medicament delivery path. The electronic circuit system is configured to output an electronic output in response to a delivery of a medicament via the medicament delivery path. In some embodiments, the electronic output can be, for example, a visual output, an audible output, and/or a haptic output.
In some embodiments, an apparatus includes a medical injector having a housing, a medicament container and a medicament delivery member. The housing defines a first region including at least the medicament container and a second region configured to receive an electronic circuit system. The first region of the housing is physically isolated from the second region of the housing. The electronic circuit system is configured to output an electronic output associated with a use of the medical injector. In some embodiments, the medical injector is configured to deliver only a single dose of medicament into a body. In other embodiments, the medical injector is configured to be reusable.
In some embodiments, an apparatus includes an electronic circuit system configured to be coupled to a medical injector such that, the electronic circuit system is physically isolated from a medicament delivery path. The electronic circuit system is configured to output an electronic output in response to the delivery of a medicament via the medicament delivery path. The electronic output can be, for example, a visual output, an audible output, and/or a haptic output.
In some embodiments, a method includes assembling a medical device configured to deliver a medicament into a body of a patient. The medical device includes a housing, a medicament container, an actuator and a safety lock. The medicament container is disposed within the housing. The actuator is configured to initiate delivery of the medicament from the medicament container when the actuator is actuated. The safety lock is configured to prevent actuation of the actuator. An electronic circuit system is coupled to the housing of the assembled medical device such that an opening defined by a substrate of the electronic circuit system is disposed about a portion of the safety lock. The electronic circuit system is configured to output an electronic output in response to a movement of the safety lock within the opening.
In some embodiments, a method includes coupling an electronic circuit system to a simulated medicament delivery device such that a portion of the housing actuates a switch of the electronic circuit system. The simulated medicament delivery device is configured to simulate an actual medicament delivery device. The electronic system is configured to output an electronic output associated with a use of the simulated medicament delivery device and a state of the switch. The electronic output can be, for example, a visual output, an audible output, and/or a haptic output.
In some embodiments, an apparatus includes a simulated medicament delivery device and an electronic circuit system. The simulated medicament delivery device, which can be, for example, a pen injector, an auto-injector, an inhaler or a transdermal delivery device, is configured to simulate an actual medicament delivery device. The simulated medicament delivery device includes a housing, a safety lock and a cover. The safety lock is configured to simulate a safety lock of the actual medicament delivery device. The cover is removably disposed about at least a portion of the housing. The electronic circuit system is configured to output a first plurality of electronic outputs when the cover is removed from the housing a first time. The electronic circuit system is configured to output a second plurality of electronic outputs when the cover is removed from the housing a second time. The second plurality of electronic outputs are different from the first plurality of electronic outputs. In some embodiments, the first and/or the second plurality of electronic outputs can be, for example, visual outputs, audible outputs, and/or haptic outputs.
In some embodiments, a processor-readable medium storing code representing instructions to cause a processor to perform a process includes code to output a first electronic output associated with a use of a simulated medicament delivery device when a cover is removed from the simulated medicament delivery device a first time. The processor-readable medium includes code to output a second electronic output associated with a use of the simulated medicament delivery device when the cover is removed a second time. The second electronic output is different from the first electronic output. The simulated medicament delivery device can be, for example, a pen injector, an auto-injector, an inhaler or a transdermal delivery device. In some embodiments, the first and/or second electronic outputs can be, for example, a visual output, an audible output, and/or a haptic output.
As used in this specification and the appended claims, the words “proximal” and “distal” refer to direction closer to and away from, respectively, an operator (e.g., surgeon, physician, nurse, technician, etc.) of the medical device. Thus, for example, the end of the medicament delivery device contacting the patient's body would be the distal end of the medicament delivery device, while the end opposite the distal end would be the proximal end of the medicament delivery device.
The medicament container 1560, which can be, for example, a pre-filled cartridge, a vial, an ampule or the like, is disposed within the first region 1157 of the housing 1110. At least a portion of the medicament delivery member 1512 is disposed within the first region 1157 of the housing 1110. In some configurations, the medicament delivery member 1512 can be in fluid communication with the medicament container 1560. In this manner, a medicament can be conveyed from the medicament container 1560 to a region outside the housing 1110 via the medicament delivery member 1512. The medicament delivery member 1512 can include, for example, a needle and/or a nozzle.
At least a portion of the electronic circuit system 1900 is disposed within the second region 1153 of the housing 1110. Accordingly, the portion of the electronic circuit system 1900 is disposed within the housing 1110 such that the portion of the electronic circuit system 1900 is fluidically and/or physically isolated from the medicament container 1560 and/or the medicament delivery member 1512.
The electronic circuit system 1900 is configured to output an electronic output OP1 associated with a use of the medical injector 1000. For example, in some embodiments, the electronic output OP1 can be associated with an instruction for using the medical injector 1000. In other embodiments, the electronic output OP1 can be a post-use instruction, such as, for example, a recorded message notifying the user that the injection is complete, instructing the user on post-injection disposal and safety procedures, instructing the user to seek post-injection medical treatment, and/or the like. In yet other embodiments, the electronic output OP1 can be associated with the patient's compliance in using medical injector 1000. In some embodiments, the electronic output OP1 can be associated with an actuation of the medical injector 1000. Said another way, the electronic circuit system 1900 can be configured to output the electronic output OP1 in response to actuation of the medical injector 1000.
The electronic output OP1 can be, for example, a visual output such as, for example, a text message to display on a screen (not shown), and/or an LED. In some embodiments, the electronic output OP1 can be an audio output, such as, for example, recorded speech, a series of tones, and/or the like. In other embodiments, the electronic output OP1 can be a wireless signal configured to be received by a remote device.
The medical injector 1000 can be any suitable medical injector for injecting medicament into a body of a patient. For example, the medical injector 1000 can be a syringe, pen injector, auto-injector or the like. In some embodiments, the medical injector 1000 can be a chronic-care injector. Said another way, the medical injector 1000 can be a reusable device containing multiple doses of medicament. For example, a medical injector 1000 having multiple doses of medicament can be used to manage insulin delivery or the delivery of other medicaments (e.g., to treat Multiple Sclerosis, Anemia, Rheumatoid Arthritis, Osteoporosis or the like), which can require daily, weekly, and/or monthly injections. In other embodiments, the medical injector 1000 can be a single-use device. Said another way, the medical injector 1000 can contain a single dose of medicament. In some embodiments, medical injector 1000 can include the same dosage of a medicament, and can be prescribed as a part of a chronic-care medicament regimen, clinical trial, or the like. In other embodiments, medical injector 1000 can include different dosages, and/or different medicament compositions.
The sidewall 1148 can be any suitable structure to isolate the first region 1157 within the housing 1110 from the second region 1153 within the housing 1110. In some embodiments, the sidewall 1148 can be rigid. In other embodiments, the sidewall 1148 can be a movable member such as, for example, a piston. In yet other embodiments, the sidewall 1148 can be a flexible member such as, for example, a diaphragm. In some embodiments, the sidewall 1148 can be constructed from a transparent material such that light can pass from the first region 1157 to the second region 1153, and vice versa. A transparent sidewall can be used in conjunction with an optical sensor. The sidewall 1148 can be integrally formed with the housing 1110 or can be formed separately from the housing 1110.
The electronic circuit system 1900 can include any suitable electronic components operatively coupled to produce and/or output the electronic output OP1 and/or to perform the functions described herein. The electronic circuit system 1900 can be similar to the electronic circuit systems described in U.S. patent application Ser. No. 11/621,236, entitled “Devices, Systems and Methods for Medicament Delivery,” filed Jan. 9, 2007, which is incorporated herein by reference in its entirety.
In use, the medicament delivery member 2512 can be in fluid communication with the medicament container 2560. In this manner, the medicament delivery member 2512 and the medicament container 2560 can define a medicament delivery path 2505 through which a medicament 2568 can be conveyed from the medicament container 2560 to a location outside the housing 2110 via the medicament delivery member 2512 as shown by arrow AA. In some embodiments, the medicament delivery path 2505 can include portions of a lumen defined by the medicament delivery member 2512 and/or the connection between the medicament delivery member 2512 and the medicament container 2560.
The electronic circuit system 2900 is coupled to the housing 2110 and is fluidically and/or physically isolated from the medicament delivery path 2505. The electronic circuit system 2900 is configured to output an electronic output OP2 in response to a delivery of the medicament 2568 via the medicament delivery path 2505. In this manner, the electronic circuit system 2900 can output the electronic output OP2 in an unobtrusive manner and/or without impeding the delivery of the medicament 2568 through the medicament delivery path 2505. In some embodiments, for example, the electronic output OP2 can be a post-use instruction, such as, for example, a recorded message notifying the user that the injection is complete, instructing the user on post-injection disposal and safety procedures, instructing the user on post-injection medical treatment, and/or the like. In other embodiments, the electronic output OP2 can be associated with the patient's compliance in using the medicament delivery device 2000. For example, in some embodiments, the electronic output OP2 can be a signal sent to a compliance tracking monitor to record the data and/or time of use of the medicament delivery device 2000.
The electronic output OP2 can be, for example, a visual output such as, for example, a text message to display on a screen (not shown), and/or an LED. In some embodiments, the electronic output OP2 can be an audio output, such as, for example, recorded speech, a series of tones, and/or the like. In other embodiments, the electronic output OP2 can be a wireless signal configured to be received by a remote device.
The medicament delivery device 2000 can be any suitable medicament delivery device for delivering the medicament 2568 to a body of a patient. For example, the medicament delivery device 2000 can be a syringe, pen injector, auto-injector, inhaler or the like. In some embodiments, the medicament delivery device 2000 can be a chronic-care delivery device. Said another way, the medicament delivery device 2000 can be a reusable device containing multiple doses of medicament 2568. In other embodiments, the medicament delivery device 2000 can be a single-use device. Said another way, the medicament delivery device 2000 can contain a single dose of medicament 2568.
The electronic circuit system 2900 can include any suitable electronic components operatively coupled to produce and/or output the electronic output OP2 and/or to perform the functions described herein. The electronic circuit system 1900 can be similar to the electronic circuit system 1900 as described above with reference to
As shown in
As shown in
The medicament cavity 4157 is configured to receive a portion of the delivery mechanism 4500. In particular, the carrier 4520, the moveable member 4530 and the needle 4512 of the medicament delivery mechanism 4500 are movably disposed in the medicament cavity 4157. The medicament cavity 4157 is in fluid communication with a region outside the housing 4110 via a needle aperture 4122.
The electronic circuit system cavity 4153 is configured to receive the electronic circuit system 4900. The housing 4110 has protrusions 4149 (see e.g.,
The electronic circuit system cavity 4153 is fluidically and/or physically isolated from the gas cavity 4154 and/or the medicament cavity 4157 by a sidewall 4148. The sidewall 4148 can be any suitable structure to isolate the electronic circuit system cavity 4153 within the housing 4110 from the gas cavity 4154 and/or the medicament cavity 4157 within the housing 4110. Similarly, the gas cavity 4154 and the medicament cavity 4157 are separated by a sidewall 4146. In some embodiments, sidewall 4146 can be similar to the sidewall 4148, which isolates the gas cavity 4154 and the medicament cavity 4157 from the electronic circuit system cavity 4153. In other embodiments the gas cavity 4154 can be fluidically and/or physically isolated from the medicament cavity 4157.
The proximal end portion 4140 of the housing 4110 includes a proximal cap 4112, a speaker protrusion 4147 (see e.g.,
As shown in
As shown in
The needle aperture 4122 is configured to allow the needle 4512 (see e.g.,
The safety lock actuator groove 4123 is configured to receive an actuator 4744 of the safety lock 4700. As described in more detail herein, the actuator 4744 is configured to engage and/or activate the electronic circuit system 4900 when the safety lock 4700 is moved with respect to the housing 4110. The safety lock aperture 4128 is configured to receive a safety lock protrusion 4742 (see e.g.,
The distal base retention recesses 4125A are configured to receive the base connection knobs 4358 of the base 4300 (see e.g.,
The base actuator groove 4124 is configured to receive an actuator 4311 of the base 4300. As described in more detail herein, the actuator 4311 of the base 4300 is configured to engage the electronic circuit system 4900 when the base 4100 is moved with respect to the housing 4110. The base rail grooves 4127 are configured to receive the guide members 4312 of the base 4300. The guide members 4312 of the base 4300 and the base rail grooves 4127 of the housing 4110 engage each other in a way that allows the guide members 4312 of the base 4300 to slide in a proximal and/or distal direction within the base rail grooves 4127 while limiting lateral movement of the guide members 4312. This arrangement allows the base 4300 to move in a proximal and/or distal direction with respect to the housing 4110 but prevents the base 4300 from moving in a lateral direction with respect to the housing 4110.
The medicament delivery mechanism 4500 includes a needle 4512, a carrier 4520, a movable member 4530, a medicament container 4560, a gas container 4570, and a release member 4540. As described above, the needle 4512, carrier 4520, movable member 4530 and medicament container 4560 are disposed within the medicament cavity 4157 of the housing 4110. The gas container 4570 and the release member 4540 are disposed within the gas cavity 4154 of the housing 4110.
The release member 4540 has a proximal end portion 4542 and a distal end portion 4544, and is movably disposed within the distal end portion 4156 of the gas cavity 4154. The proximal end portion 4542 of the release member 4540 includes a sealing member 4545 and a puncturer 4541. The sealing member 4545 is configured to engage the sidewall of the housing 4110 defining the gas cavity 4154 such that the proximal end portion 4155 of the gas cavity 4154 is fluidically isolated from the distal end portion 4156 of the gas cavity 4154. In this manner, when gas is released from the gas container 4570, the gas contained in the proximal end portion 4155 of the gas cavity 4154 is unable to enter the distal end portion 4156 of the gas cavity 4154. The puncturer 4541 of the proximal end portion 4542 of the release member 4540 is configured to contact and puncture a frangible seal 4573 on the gas container 4570 when the release member 4540 moves proximally within the gas cavity 4154, as shown by the arrow BB in
The distal end portion 4544 of the release member 4540 includes extensions 4552. The extensions 4552 include projections 4547 that include tapered surfaces 4549 and engagement surfaces 4548. Further, the extensions 4552 define an opening 4554 between the extensions 4552. The tapered surfaces 4549 of the projections 4547 are configured to contact protrusions 4313 on a proximal surface 4310 of the base 4300 (see e.g.,
The opening 4554 defined by the extensions 4552 is configured to receive the safety lock protrusion 4742 of the safety lock 4700 (see e.g.,
The gas container 4570 includes a distal end portion 4572 and a proximal end portion 4576, and is configured to contain a pressurized gas. The distal end portion 4572 of the gas container 4570 contains a frangible seal 4573 configured to break when the puncturer 4541 of the proximal end portion 4542 of the release member 4540 contacts the frangible seal 4573. The gas container retention member 4580 of the proximal cap 4112 of the housing 4110 is configured to receive and/or retain the proximal end portion 4576 of the gas container 4570. Said another way, the position of the gas container 4570 within the gas cavity 4154 is maintained by the gas container retention member 4580.
The medicament container 4560 of the medicament delivery mechanism 4500 has a distal end portion 4562 and a proximal end portion 4566, and is configured to contain a medicament. The distal end portion 4562 of the medicament container 4560 contains a seal 4523. The seal 4523 is configured to burst when punctured by the proximal end 4516 of the needle 4512, as described below. The proximal end portion 4566 of the medicament container 4560 is configured to receive a piston portion 4534 of the movable member 4530.
The movable member 4530 of the medicament delivery mechanism 4500 is movably disposed within the medicament cavity 4157. The movable member 4530 includes a piston portion 4534 having a plunger at the distal end portion of the piston portion 4534. The piston portion 4534 is configured to move within the medicament container 4560. In this manner, the piston portion 4534 of the movable member 4530 can apply pressure to a medicament contained in the medicament container 4560. The piston portion 4534 can be constructed of a resilient, durable, and/or sealing material, such as a rubber.
The carrier 4520 of the medicament delivery mechanism 4500 includes a distal end portion 4522 and a proximal end portion 4526. The medicament container 4560 is coupled to the carrier 4520 via a “snap-fit” connection (not shown) such that the medicament container 4560 can move relative to the carrier 4520 between a first configuration and a second configuration during an injection event. In the first configuration, the carrier 4520 is configured to move within the medicament cavity 4157 such that movement of the carrier 4520 within the medicament cavity 4157 causes contemporaneous movement of the medicament container 4560 within the medicament cavity 4157. The proximal end portion 4516 of the needle 4512 is spaced apart from the seal 4523 of the medicament container 4560 when the carrier 4520 is in the first configuration. In the second configuration, the medicament container 4560 releases from the “snap-fit” causing the medicament container 4560 to move distally with respect to the carrier 4520, causing the proximal end portion 4516 of the needle 4512 to pierce the seal 4523. In this manner, the needle 4512 can be selectively placed in fluid communication with the medicament container 4560 to define a medicament delivery path (not shown).
The electronic circuit system housing 4170 of the electronic circuit system 4900 includes a distal end portion 4180 and a proximal end portion 4190. The proximal end portion 4190 includes connection protrusions 4171A and a battery clip protrusion 4173. The connection protrusions 4171A extend from the proximal end portion 4190 of the electronic circuit system housing 4170, and are configured to be disposed within the connection apertures 4152 of the housing 4110, as described above. In this manner, the electronic circuit system 4900 can be coupled to the housing 4110 within the electronic circuit system cavity 4153. In other embodiments, the electronic circuit system 4900 can be coupled to the housing 4110 by other suitable means such as an adhesive, a clip and/or the like. As described in more detail herein, the battery clip protrusion 4173 is configured to hold the battery clip 4910 in place.
The proximal end portion 4190 of the electronic circuit system housing 4170 defines multiple sound apertures 4191. The audible output device 4956 is disposed against the proximal end portion 4190 of the electronic circuit system housing 4170 such that the front face of the audible output device 4956 is disposed adjacent the sound apertures 4191. In this manner, the sound apertures 4191 are configured to allow sound from an audio output device 4956 to pass from the audio output device 4956 to a region outside of the housing 4110.
As shown in
The connection protrusion 4171B extends from the distal end portion 4180 of the electronic circuit system housing 4170, and is configured to attach the electronic circuit system 4900 to the housing 4110, as described above. The stiffening protrusion 4174 is configured to have at least a portion received within and/or accessible via the aperture 4145 in the housing 4110 (see e.g.,
The safety lock actuator groove 4182 of the electronic circuit system housing 4170 is configured to be disposed adjacent the safety lock actuator groove 4123 of the distal end portion 4120 of the housing 4110. In this manner, the safety lock actuator groove 4182 of the electronic circuit system housing 4170 and the safety lock actuator groove 4123 of the distal end portion 4120 of the housing 4110 collectively receive the actuator 4744 of the safety lock 4700, which is described in more detail herein. Similarly, the base actuator groove 4183 of the electronic circuit system housing 4170 is configured to be disposed about the base actuator groove 4124 of the distal end portion 4120 of the housing 4110. The base actuator groove 4183 of the electronic circuit system housing 4170 and the base actuator groove 4124 of the distal end portion 4120 of the housing 4110 collectively receive the actuator 4311 of the base 4300, which is described in more detail herein.
The printed circuit board 4922 of the electronic circuit system 4900 includes a substrate 4924, a first actuation portion 4926 and a second actuation portion 4946. The substrate 4924 of the printed circuit board 4922 includes the electrical components necessary for the electronic circuit system 4900 to operate as desired. For example, the electrical components can be resistors, capacitors, inductors, switches, microcontrollers, microprocessors and/or the like. The substrate 4924 includes a series of electrical conductors, such as for example, copper traces, etched thereon. The substrate 4924 can be constructed from any material having suitable electrical properties, mechanical properties and flexibility, such as, for example Mylar®, Kapton® or impregnated paper. A mask layer 4925 (shown as being transparent in
As shown in
The opening 4928 is defined adjacent the first electrical conductor 4934 that electronically couples the components included in the electronic circuit system 4900. The first electrical conductor 4934 includes a first switch 4972, which can be, for example a frangible portion of the first electrical conductor 4934. In use, when the safety lock 4700 is moved from a first position (see e.g.,
The second actuation portion 4946 includes a second electrical conductor 4935 and defines an opening 4945, having a boundary 4949 and a tear propagation limit aperture 4948. As shown in
The second electrical conductor 4935 includes a second switch 4973 disposed between the opening 4945 and the tear propagation limit aperture 4948, which can be, for example, a frangible portion of the second electrical conductor 4935. In use, when the base 4300 is moved from its first position to its second position (see e.g.,
The battery assembly 4962 of the electronic circuit system 4900 comprises two batteries stacked on top of one another. The battery assembly 4962 has a first surface 4964 and a second surface 4966. The first surface 4964 of the battery assembly 4962 can contact an electrical contact (not shown) disposed on the substrate 4924. The second surface 4966 of the battery assembly 4962 is configured to contact a contact portion 4918 of a distal end portion 4916 of a battery clip 4910. When both the electrical contact of the substrate 4924 and the contact portion 4918 of the distal end portion 4916 of the battery clip 4910 contact the battery assembly 4962, the batteries of the battery assembly 4962 are placed in electrical communication with the electronic circuit system 4900. Said another way, when the electrical contact of the substrate 4924 and the contact portion 4918 of the distal end portion 4916 of the battery clip 4910 contact the battery assembly 4962, the battery assembly 4962 is configured to supply power to the electronic circuit system 4900.
The battery clip 4910 (shown in
The distal end portion 4916 of the battery clip 4910 includes a contact portion 4918 and an angled portion 4917. As described above, the contact portion 4918 is configured to contact the second surface 4916 of the battery assembly 4962 to place the battery assembly 4962 in electrical communication with the electronic circuit system 4900. The angled portion 4917 of the distal end portion 4916 of the battery clip 4910 is configured to allow a proximal end portion 4236 of a battery isolation protrusion 4235 (see e.g.,
The audio output device 4956 of the electronic circuit system 4900 is configured to output audible sound to a user in response to a use of the medical injector 4000. In some embodiments, the audible output device 4956 can be a speaker. In some embodiments, the audible sound can be, for example, associated with a recorded message and/or a recorded speech. In other embodiments, the audible instructions can be an audible beep, a series of tones and/or or the like.
In other embodiments, the medical injector 4000 can have a network interface device (not shown) configured to operatively connect the electronic circuit system 4900 to a remote device (not shown) and/or a communications network (not shown). In this manner, the electronic circuit system 4900 can send information to and/or receive information from the remote device. The remote device can be, for example, a remote communications network, a computer, a compliance monitoring device, a cell phone, a personal digital assistant (PDA) or the like. Such an arrangement can be used, for example, to download replacement processor-readable code from a central network to the electronic circuit system 4900. In some embodiments, for example, the electronic circuit system 4900 can download information associated with a medical injector 4000, such as an expiration date, a recall notice, updated use instructions or the like. Similarly, in some embodiments, the electronic circuit system 4900 can upload compliance information associated with the use of the medical injector 4000 via the network interface device.
The distal end portion 4230 of the cover 4200 includes a battery isolation protrusion 4235. The battery isolation protrusion 4235 includes a proximal end portion 4236 and a tapered portion 4237. The proximal end portion 4236 of the battery isolation protrusion 4235 is configured to be removably disposed between the second surface 4966 of the battery assembly 4962 and the contact portion 4918 of the distal end portion 4916 of the battery clip 4910, as described above.
The proximal surface 4740 of the safety lock 4700 includes a safety lock protrusion 4742, a stopper 4743, an actuator 4744 and two opposing pull tabs 4741. As described above, when the safety lock 4700 is in a first (locked) position, the safety lock protrusion 4742 is configured to be disposed in the opening 4554 defined by the extensions 4552 of the distal end portion 4544 of the release member 4540. Accordingly, the safety lock protrusion 4742 is configured to prevent the extensions 4552 from moving closer to each other, thereby preventing proximal movement of the release member 4540 of the medicament delivery mechanism 4500 and/or delivery of a medicament. The stopper 4743 of the safety lock 4700 is a protrusion extending from the proximal surface 4740 of the safety lock 4700. The stopper 4743 is configured to contact a portion of the housing 4110 to limit the proximal movement of the safety lock 4700 relative to the housing 4110. In other embodiments, the stopper 4743 can be any structure configured to limit the proximal movement of the safety lock 4700.
The actuator 4744 of the safety lock 4700 has an elongated portion 4745 and a protrusion 4746. The elongated portion 4745 extends in a proximal direction from the proximal surface 4740. In this manner, the elongated portion 4745 can extend through a safety lock actuator opening 4356 of the base 4300 (see e.g.,
The pull tabs 4741 of the safety lock 4700 include a grip portion 4747 and indicia 4748. The grip portion 4747 of the pull tabs 4741 provides an area for the user to grip and/or remove the safety lock 4700 from the rest of the medicament delivery system 4700. The indicia 4748 provides instruction on how to remove the safety lock 4700. In some embodiments, for example, the indicia 4748 can indicate the direction the user should pull the safety lock 4700 to remove the safety lock 4700.
As shown in
The distal end portion 4724 of the needle sheath 4720 has an angled ridge 4725. The angled ridge 4725 is configured to allow the proximal end portion 4722 of the needle sheath 4720 to irreversibly move through the needle sheath aperture 4770 of the safety lock 4700 in a distal direction. Said another way, the angled ridge 4725 can be configured in such a way as to allow the proximal end portion 4722 of the needle sheath 4720 to move through the needle sheath aperture 4770 in a distal direction, but not in a proximal direction. The needle sheath aperture 4770 has retaining tabs 4771 configured to engage the proximal end of the angled ridge 4725 when the needle sheath 4720 is moved in a proximal direction. In this manner, the retaining tabs 4771 prevent the proximal movement of the needle sheath with respect to the safety lock 4700. Further, the retaining tabs 4771 are configured to engage the proximal end of the angled ridge 4725 when the safety lock 4700 is moved in a distal direction. Said another way, as shown in
The proximal surface 4310 of the base 4300 includes an actuator 4311, guide members 4312, and protrusions 4313. The actuator 4311 is an elongate member configured to engage the substrate 4924 of the electronic circuit system 4900. As described above, the opening 4945 of the second actuation portion 4946 is configured to receive the actuator 4311 of the base 4300. The guide members 4312 of the base 4300 are configured to engage and/or slide within the base rail grooves 4127 of the housing 4110, as described above. The protrusions 4313 of the base 4300 are configured to engage the tapered surfaces 4549 of the extensions 4552 of the release member 4540. As described in further detail herein, when the safety lock 4700 is removed and the base 4300 is moved in a proximal direction with respect to the housing 4110, the protrusion 4313 of the base 4300 are configured to move the extensions 4552 of the release member 4540 closer to each other, actuating the medicament delivery mechanism 4500. As described above, the base connection knobs 4358 are configured to engage the base retention recesses 4125A, 4125B in a way that allows proximal movement of the base 4300 but limits distal movement of the base 4300.
As shown in
When power is provided, as described above, the electronic circuit system 4900 can output one or more predetermined electronic outputs. For example, in some embodiments, the electronic circuit system 4900 can output an electronic signal associated with recorded speech to the audible output device 4956. Such an electronic signal can be, for example, associated with a .WAV file that contains a recorded instruction instructing the user in the operation of the medical injector 4000. Such an instruction can state, for example, “remove the safety tab near the base of the auto-injector.” The electronic circuit system 4900 can simultaneously output an electronic signal to one and/or both of the LEDs 4958A, 4958B thereby causing one and/or both of the LEDs 4958A, 4958B to flash a particular color. In this manner, the electronic circuit system 4900 can provide both audible and visual instructions to assist the user in the initial operation of the medical injector 4000.
In other embodiments, the electronic circuit system 4900 can output an electronic output associated with a description and/or status of the medical injector 4000 and/or the medicament contained therein. For example, in some embodiments, the electronic circuit system 4900 can output an audible message indicating the type of medicament contained in the medical injector 4000, the expiration date of the medicament, the dosage of the medicament or the like.
As described above, the medical injector 4000 can be can be repeatedly moved between the first configuration and the second configuration when the cover 4200 is moved repeatedly between the first position and the second position respectively. Said another way, the cover 4200 can be removed and replaced about the housing 4110 any number of times. When the cover 4200 is moved from the second position to the first position, the battery isolation protrusion 4235 is inserted between the battery clip 4910 and the second surface 4966 of the battery assembly 4962, deactivating the electronic circuit system 4900. When the cover is moved from the first position to the second position a second time, the electronic circuit system 4900 is once again activated. In this manner, the cover 4200 can be removed and the electronic circuit system 4900 can output an electronic output without compromising the sterility of the needle 4512.
After the cover 4200 is removed from the housing 4110, the medical injector 4000 can be moved from the second configuration to a third configuration by moving the safety lock 4700 from a first position to a second position. The safety lock 4700 is moved from a first position to a second position by moving the safety lock 4700 with respect to the housing 4110 in the direction shown by the arrow FF in
In some embodiments, the first actuation portion 4926 and the actuator 4744 can be configured such that the actuator 4744 must move a predetermined distance before the actuator 4744 engages the boundary 4929 of the opening 4928. For example, in some embodiments, the actuator 4744 must move approximately 0.200 inches before the actuator 4744 engages the boundary 4929 of the opening 4928. In this manner, the safety lock 4700 can be moved slightly without irreversibly moving the first switch 4972 of the electronic circuit system 4900 to the second state. Accordingly, this arrangement will permit the user to inadvertently and/or accidentally move the safety lock 4700 without actuating the electronic circuit system 4900.
In some embodiments, the electronic circuit system 4900 can be configured to output the status message for a predetermined time period, such as, for example, five seconds. After the predetermined time period has elapsed, the electronic circuit system 4900 can output an audible message further instructing the user in the operation of the medical injector 4000. Such an instruction can state, for example, “Place the base of the auto-injector against the patient's thigh. To complete the injection, press the base firmly against the patient's thigh.” In some embodiments, the electronic circuit system 4900 can simultaneously output an electronic signal to one and/or both of the LEDs 4958A, 4958B, thereby causing one and/or both of the LEDs 4958A, 4958B to flash a particular color. In this manner, the electronic circuit system 4900 can provide both audible and/or visual instructions to assist the user in the placement and actuation of the medical injector 4000. In some embodiments, the electronic circuit system 4900 can be configured to repeat the instructions after a predetermined time period has elapsed.
As described above, in other embodiments, the medical injector 4000 can have a network interface device (not shown) configured to operatively connect the electronic circuit system 4900 to a remote device (not shown) and/or a communications network (not shown). In this manner, the electronic circuit system 4900 can send a wireless signal notifying a remote device that the safety lock 4700 of the medical injector 4000 has been removed and that the medical injector 4000 has been armed.
After the safety lock 4700 is moved from the first position to the second position, the medical injector 4000 can be moved from the third configuration to a fourth configuration by moving the base 4300 from a first position to a second position. The base 4300 is moved from its first position to its second position by placing the medical injector 4000 against the body of the patient and moving the base 4300 with respect to the housing 4110 in the direction shown by the arrow GG in
When the base 4300 is moved from the first position to the second position, the medicament delivery mechanism 4500 is actuated such that the puncturer 4541 of the release member 4540 is brought in contact with and/or punctures the frangible seal 4573 of the gas container 4570. In some embodiments, the movement of the release member 4540 can be caused by a spring (not shown in
After the carrier 4520 and/or the needle 4512 have moved within the medicament cavity 4157 a predetermined distance, the carrier 4520 and the medicament container 4560 are moved from the first configuration to a second configuration. In the second configuration of the carrier 4520, the medicament container 4560 is released from the “snap-fit” allowing the medicament container 4560 and the movable member 4530 to continue to move in a distal direction relative to the carrier 4520. Said another way, the medicament container 4560 is configured to slidably move within the carrier 4520 when the carrier is moved from the first configuration to the second configuration. As the medicament container 4560 continues to move within the carrier 4520, the proximal end portion 4516 of the needle 4512 contacts and punctures the seal 4523 of the medicament container 4560. This allows the medicament contained in the medicament container 4560 to flow into the lumen (not shown) defined by the needle 4512, thereby defining a medicament delivery path.
As the medicament container 4560 contacts the distal end of the carrier 4520, the medicament container 4560 stops moving within the carrier 4520 while the movable member 4530 continues to move in a distal direction. This causes the piston portion 4534 of the movable member 4530 to sealingly slide and/or move within the medicament container 4560 containing a liquid medicament. As the piston portion 4534 of the movable member 4530 sealingly slides and/or moves within the medicament container 4560, the piston portion 4534 generates a pressure upon the medicament contained within the medicament container 4560, thereby allowing at least a portion of the medicament to flow out of the medicament container 4560 and into the lumen defined by the needle 4512. The medicament is delivered to a body of a user via the medicament delivery path defined by the medicament container 4560 and the needle 4512.
As described above, the actuator 4538 of the base 4300 actuates the electronic circuit 4900 to trigger a predetermined output or sequence of outputs when the base 4520 is moved from its first position to its second position (see, e.g.,
In some embodiments, the second actuation portion 4946 and the actuator 4538 can be configured such that the base 4500 and/or the actuator 4538 must move a predetermined distance before the actuator 4538 engages the boundary 4949 of the opening 4945. For example, in some embodiments, the actuator 4538 must move approximately 0.200 inches before the actuator 4538 engages the boundary 4949 of the opening 4945. In this manner, the base 4700 can be moved slightly without irreversibly moving the second switch 4973 of the electronic circuit system 4900 to the second state. Accordingly, this arrangement will permit the user to inadvertently and/or accidentally move the base 4500 without actuating the electronic circuit system 4900.
Although the electronic circuit system 4900 is shown and described above as having two irreversible switches (e.g., switch 4972 and switch 4973), in other embodiments, an electronic circuit system can have any number of switches. Moreover, such switches can be either reversible or irreversible. For example,
The medicament delivery device 5000 is similar to the medical injector 4000 described above. As shown in
As shown in
The electronic circuit system cavity 5153 is configured to receive the electronic circuit system 5900. As described above, the electronic circuit system cavity 5153 is fluidically and/or physically isolated from the gas cavity and/or the medicament cavity by a sidewall 5148. The housing 5110 has protrusions 5149 configured to stabilize the electronic circuit system 5900 when the electronic circuit system 5900 is disposed within the electronic circuit system cavity 5153. The housing 5110 also defines connection apertures (not shown) configured to receive connection protrusions 5171 of the electronic circuit system 5900 (see e.g.,
The housing 5110 includes an actuation protrusion 5114 disposed within the electronic circuit system cavity 5153. As described in more detail herein, an angled end portion 5115 of the actuation protrusion 5114 of the housing 5110 is configured to engage a third actuation portion 5976 of a substrate 5924 of the electronic circuit system 5900 when the electronic circuit system 5900 is coupled to the housing 5110.
As shown in
As shown in
The electronic circuit system 5900 also includes a processor 5950 configured to process electronic inputs (e.g., from input switches) and produce electronic outputs. As described herein, such electronic outputs can include audio or visual outputs associated with a use of the medicament delivery device 5000. The processor 5950 can be a commercially-available processing device dedicated to performing one or more specific tasks. For example, in some embodiments, the processor 5950 can be a commercially-available microprocessor, such as the Sonix SNC 12060 voice synthesizer. Alternatively, the processor 5950 can be an application-specific integrated circuit (ASIC) or a combination of ASICs, which are designed to perform one or more specific functions. In yet other embodiments, the processor 5950 can be an analog or digital circuit, or a combination of multiple circuits.
The processor 5950 can include a memory device (not shown) configured to receive and store information, such as a series of instructions, processor-readable code, a digitized signal, or the like. The memory device can include one or more types of memory. For example, the memory device can include a read only memory (ROM) component and a random access memory (RAM) component. The memory device can also include other types of memory suitable for storing data in a form retrievable by the processor 5950, for example, electronically-programmable read only memory (EPROM), erasable electronically-programmable read only memory (EEPROM), or flash memory.
The first actuation portion 5926 and the second actuation portion 5946 are similar to the first actuation portion 4926 and the second actuation portion 4946 of the electronic circuit system 4900, described above (see e.g.,
The third electrical conductor 5936 includes the electronic circuit system configuration switch 5974 (see e.g.,
The tear propagation limit aperture 5978 is configured to limit the propagation of the tear in the substrate 5924. Said another way, the tear propagation limit aperture 5978 is configured to ensure that the tear in the substrate 5924 does not extend beyond the tear propagation limit aperture 5978. The tear propagation limit aperture 5978 can be any shape configured to limit the propagation of a tear and/or disruption of the substrate 5924. For example, the tear propagation limit aperture 5978 can be oval shaped. In other embodiments, the boundary of the tear propagation limit aperture 5978 can be reinforced to ensure that the tear in the substrate 5924 does not extend beyond the tear propagation limit aperture 5978. The angled end portion 5115 of the actuation protrusion 5114 ensures that the tear in the substrate 5924 propagates in the desired direction. Said another way, the angled end portion 5115 of the actuation protrusion 5114 ensures that the tear in the substrate 5924 occurs between the actuation aperture 5975 and the tear propagation limit aperture 5978.
When the actuation protrusion 5114 of the housing 5110 moves irreversibly the electronic circuit system configuration switch 5974 of the electronic circuit system 5900 from the first state to the second state, the electronic circuit system 5900 can be moved between a first configuration and a second configuration. For example, in some embodiments, irreversibly moving the electronic circuit system configuration switch 5974 of the electronic circuit system 5900 to the second state places the electronic circuit system 5900 in the second configuration such that when power is applied to the electronic circuit system 5900, the electronic circuit system 5900 recognizes that the medicament delivery device 5000 is a certain type of medicament delivery device and/or is in a certain configuration. In some embodiments, the housing can be devoid of the actuation protrusion 5114, thus the electronic circuit system configuration switch 5974 is maintained in its first state when the electronic circuit system 5900 is attached to the housing 5110. In this manner, the electronic circuit system configuration switch 5974 can enable the electronic circuit system 5900 to be used in different types and/or configurations of medicament delivery devices. The dual functionality of the electronic circuit system 5900 enables production of the same electronic circuit system 5900 for multiple devices, thereby permitting mass production and decreasing the cost of production of the electronic circuit system 5900.
For example, in some embodiments the electronic circuit system 5900 can be used in either an actual medicament delivery device or a simulated medicament delivery device. A simulated medicament delivery device can, for example, correspond to an actual medicament delivery device and can be used, for example, to train a user in the operation of the corresponding actual medicament delivery device.
The simulated medicament delivery device can simulate the actual medicament delivery device in any number of ways. For example, in some embodiments, the simulated medicament delivery device can have a shape corresponding to a shape of the actual medicament delivery device, a size corresponding to a size of the actual medicament delivery device and/or a weight corresponding to a weight of the actual medicament delivery device. Moreover, in some embodiments, the simulated medicament delivery device can include components that correspond to the components of the actual medicament delivery device. In this manner, the simulated medicament delivery device can simulate the look, feel and sounds of the actual medicament delivery device. For example, in some embodiments, the simulated medicament delivery device can include external components (e.g., a housing, a needle guard, a sterile cover, a safety lock or the like) that correspond to external components of the actual medicament delivery device. In some embodiments, the simulated medicament delivery device can include internal components (e.g., an actuation mechanism, a compressed gas source, a medicament container or the like) that correspond to internal components of the actual medicament delivery device.
In some embodiments, however, the simulated medicament delivery device can be devoid of a medicament and/or those components that cause the medicament to be delivered (e.g., a needle, a nozzle or the like). In this manner, the simulated medicament delivery device can be used to train a user in the use of the actual medicament delivery device without exposing the user to a needle and/or a medicament. Moreover, the simulated medicament delivery device can have features to identify it as a training device to prevent a user from mistakenly believing that the simulated medicament delivery device can be used to deliver a medicament. For example, in some embodiments, the simulated medicament delivery device can be of a different color than a corresponding actual medicament delivery device. Similarly, in some embodiments, the simulated medicament delivery device can include a label clearly identifying it as a training device.
The actuation of the medicament delivery device configuration switch 5974 can configure the electronic circuit system 5900 to output a different electronic output when the medicament delivery device 5000 is a simulated medical injector than when the medicament delivery device 5000 is an actual medical injector. Said yet another way, the electronic circuit system 5900 can be configured to output a first series of electronic outputs when the electronic circuit system configuration switch 5974 is in the first state and a second series of electronic outputs when the electronic circuit system configuration switch 5974 is in the second state. In this manner, the electronic circuit system configuration switch 5974 can enable the same electronic circuit system 5900 to be used in both simulated medicament delivery devices and actual medicament delivery devices. When used on an actual medicament delivery device, for example, the housing can be devoid of the actuation protrusion 5114. The dual functionality of the electronic circuit system 5900 can decrease the cost of production of the electronic circuit system 5900 of the medicament delivery device 5000.
In other embodiments, moving the electronic circuit system configuration switch 5974 to the second state can place the electronic circuit system 5900 in any number of different functional configurations. For example, moving the electronic circuit system configuration switch 5974 from the first state to the second state can indicate the type of medicament in the medicament container, the dosage of the medicament and/or the language of the audible electronic outputs output by the electronic circuit system 5900.
In still other embodiments, any number of electronic circuit system configuration switches can be used. For example, multiple switches can be used to configure the electronic circuit system 5900 to output usage instructions in any number of languages. For example, if an electronic circuit system contained three configuration switches (e.g., switches A, B and C), switch A can correspond to English instructions, switch B to Spanish instructions and switch C to German instructions. Further, moving both switch A and B to the second state might correspond to French instructions. In this manner, a single electronic circuit system 5900 can be configured to output instructions in multiple languages.
After the medical device is assembled, at least a portion of the medical device can optionally be sterilized, 104. Various sterilization techniques may be utilized. In some embodiments, a suitable sterilization technique includes the use of one or more of ethylene oxide, gamma radiation, e-beam radiation, ultraviolet radiation, steam, plasma, or hydrogen peroxide. In some embodiments, the needle is sterilized prior to installing the needle cover. In some embodiments, the needle is sterilized after the needle cover is installed. For example, in some embodiments, the needle cover is installed and then a gas sterilant is conveyed through at least a portion of the needle cover. The needle is sterilized using a gas sterilization technique that can penetrate one or more pores of a porous needle cover. In some embodiments, the needle can be sterilized using a gas sterilization technique that can penetrate one or more pores of a porous needle cover, but that will not react with a medicament in a medicament container disposed in the housing.
An electronic circuit system is then coupled to the housing of the assembled medical device, 106. The electronic circuit system is coupled to the housing such that an opening defined by a substrate of the electronic circuit system is disposed about a portion of the safety lock. The electronic circuit system is configured to output an electronic output in response to a movement of the safety lock within the opening. In some embodiments, for example, the electronic circuit system can be similar to the electronic circuit system 4900 of the medical injector 4000 and/or the electronic circuit system 5900 of the medicament delivery device 5000, as described above. In some embodiments, the electronic output can be, for example, a visual output, an audible output, and/or a haptic output, such as those described above. In other embodiments, the electronic output can be a wireless signal configured to be received by a remote device.
After the electronic circuit system is coupled to the housing, a cover can optionally be disposed about the medical device, 108. The cover can have a protrusion disposed between a battery and a battery contact portion of the electronic circuit system. In some embodiments, for example, the cover can be similar to the cover 4200 of the medical injector 4000 and/or the cover 5200 of the medical injector 5000.
The electronic circuit system is then coupled to the simulated medicament delivery device such that a portion of the housing actuates a switch of the electronic circuit system, 126. The electronic circuit system is configured to output an electronic output associated with a use of the simulated medicament delivery device and a state of the switch. The switch can be similar to the electronic circuit system configuration switch 5974 of the medicament delivery device 5000. For example, the electronic circuit system can output a first electronic output associated with a use of the simulated medicament delivery device when the switch is in a first state and a second electronic output associated with a use of the simulated medicament delivery device when the switch is in a second state. In some embodiments, the electronic output can be, for example, a visual output, an audible output, and/or a haptic output, such as those described above. In other embodiments, the electronic output can be a wireless signal configured to be received by a remote device. As described above, any number of switches can be disposed on the electronic circuit system.
In some embodiments, an electronic self-test can be used to verify the integrity of an electronic circuit system and/or the switches of a medicament delivery device.
In other embodiments, different electronic output sequences can be used to indicate and/or test different modes of the medical injector. For example, the LEDs could blink in a third sequence to indicate a Spanish medical injector. Additionally, any number of self tests can be used to determine the state of each switch of the electronic circuit system. Further, the integrity of any number of electronic components of the medicament delivery device can be tested by the self-test. For example, the integrity of the LEDs and/or audio output device can be tested using a similar self-test as the one described above.
While various embodiments of the invention have been described above, it should be understood that they have been presented by way of example only, and not limitation. Where methods described above indicate certain events occurring in certain order, the ordering of certain events may be modified. Additionally, certain of the events may be performed concurrently in a parallel process when possible, as well as performed sequentially as described above.
For example, in some embodiments, the sidewall of the housing of a medicament delivery device can be rigid. In other embodiments, the sidewall can be a movable member such as, for example, a piston. In yet other embodiments, the sidewall can be a flexible member such as, for example, a diaphragm. In some embodiments, the sidewall can be transparent allowing light to pass from a first region to a second region and vice versa. A transparent sidewall can be used in conjunction with an optical sensor. The sidewall can be integrally formed with the housing or can be separately formed.
In other embodiments, the medicament container can be substantially cylindrical with a substantially round and/or substantially elliptical cross-sectional shape. Thus, the medicament container can define a longitudinal axis, the longitudinal axes of the medicament container can be parallel, non-coaxial, and/or co-planar. The longitudinal axis of the medicament container can be co-axial with a longitudinal axis of the piston portion of a movable member 4530. In still other embodiments, a medicament delivery device can contain multiple medicament containers and thus, multiple doses of medicament.
Although medical devices having two LEDs and an audio output device have been shown, in other embodiments the medical device might have any number of LEDs and/or audio output devices. Additionally, other types of output devices, such as haptic output devices, can be used.
Although various embodiments have been described as having particular features and/or combinations of components, other embodiments are possible having a combination of any features and/or components from any of embodiments where appropriate. For example, electrical circuit system 4900 can include an electronic circuit system configuration switch similar to that of electrical circuit system 5900.
This application is a continuation of U.S. patent application Ser. No. 13/550,893, entitled “Medicament Delivery Device Having an Electronic Circuit System,” filed Jul. 17, 2012, which is a continuation of U.S. patent application Ser. No. 12/119,016, now U.S. Pat. No. 8,231,573, entitled “Medicament Delivery Device Having an Electronic Circuit System,” filed May 12, 2008, which is a continuation-in-part of U.S. patent application Ser. No. 11/679,331, entitled “Medical Injector Simulation Device,” filed Feb. 27, 2007, which is a continuation-in-part of U.S. patent application Ser. No. 11/671,025, now U.S. Pat. No. 8,172,082, entitled “Devices, Systems and Methods for Medicament Delivery,” filed Feb. 5, 2007, which is a continuation-in-part of U.S. patent application Ser. No. 11/621,236, now U.S. Pat. No. 7,731,686, entitled “Devices, Systems and Methods for Medicament Delivery,” filed Jan. 9, 2007, which is a continuation-in-part of U.S. patent application Ser. No. 10/572,148, now U.S. Pat. No. 7,749,194, entitled “Devices, Systems and Methods for Medicament Delivery,” filed Mar. 16, 2006, which is a national stage filing under 35 U.S.C. § 371 of International Patent Application No. PCT/US2006/003415, entitled “Devices, Systems and Methods for Medicament Delivery,” filed Feb. 1, 2006, which claims priority to U.S. Provisional Application Ser. No. 60/648,822, entitled “Devices, Systems and Methods for Medicament Delivery,” filed Feb. 1, 2005 and U.S. Provisional Application Ser. No. 60/731,886, entitled “Auto-Injector with Feedback,” filed Oct. 31, 2005, each of which is incorporated herein by reference in its entirety. U.S. patent application Ser. Nos. 11/621,236, 11/679,331 and 11/671,025 also claim priority to U.S. Provisional Application Ser. No. 60/787,046, entitled “Devices, Systems and Methods for Medicament Delivery,” filed Mar. 29, 2006, which is incorporated herein by reference in its entirety.
Number | Name | Date | Kind |
---|---|---|---|
2277907 | Goodale, Jr. et al. | Mar 1942 | A |
2960087 | Uytenbogaart | Nov 1960 | A |
3055362 | Uytenbogaart | Sep 1962 | A |
3115133 | Morando | Dec 1963 | A |
3426448 | Sarnoff | Feb 1969 | A |
3688765 | Gasaway | Sep 1972 | A |
3768472 | Hodosh et al. | Oct 1973 | A |
3795061 | Sarnoff et al. | Mar 1974 | A |
3945379 | Pritz et al. | Mar 1976 | A |
4108177 | Pistor | Aug 1978 | A |
4124024 | Schwebel et al. | Nov 1978 | A |
4149394 | Sornes | Apr 1979 | A |
4226235 | Sarnoff et al. | Oct 1980 | A |
4258713 | Wardlaw | Mar 1981 | A |
4360019 | Partner et al. | Nov 1982 | A |
4424057 | House | Jan 1984 | A |
4441629 | Mackal | Apr 1984 | A |
4484910 | Sarnoff | Nov 1984 | A |
4573976 | Sampson et al. | Mar 1986 | A |
4596556 | Morrow et al. | Jun 1986 | A |
4610666 | Pizzino | Sep 1986 | A |
4613328 | Boyd | Sep 1986 | A |
4617557 | Gordon | Oct 1986 | A |
4624660 | Mijers et al. | Nov 1986 | A |
4640686 | Dalling et al. | Feb 1987 | A |
4643721 | Brunet | Feb 1987 | A |
4666430 | Brown et al. | May 1987 | A |
4673657 | Christian | Jun 1987 | A |
4689042 | Sarnoff et al. | Aug 1987 | A |
4693708 | Wanderer et al. | Sep 1987 | A |
4781697 | Slaughter | Nov 1988 | A |
4782841 | Lopez | Nov 1988 | A |
4784652 | Wikström | Nov 1988 | A |
4795433 | Sarnoff | Jan 1989 | A |
4822340 | Kamstra | Apr 1989 | A |
4826489 | Haber | May 1989 | A |
4853521 | Claeys et al. | Aug 1989 | A |
4865582 | Sibalis | Sep 1989 | A |
4874382 | Lindemann et al. | Oct 1989 | A |
4894054 | Miskinyar | Jan 1990 | A |
4906235 | Roberts | Mar 1990 | A |
4915695 | Koobs | Apr 1990 | A |
4941880 | Burns | Jul 1990 | A |
4959056 | Dombrowski et al. | Sep 1990 | A |
4968302 | Schluter et al. | Nov 1990 | A |
4983164 | Hook et al. | Jan 1991 | A |
5000736 | Kaufhold, Jr. et al. | Mar 1991 | A |
5024656 | Gasaway et al. | Jun 1991 | A |
5037306 | van Schoonhoven | Aug 1991 | A |
5038023 | Saliga | Aug 1991 | A |
5041088 | Ritson et al. | Aug 1991 | A |
5042977 | Bechtold et al. | Aug 1991 | A |
5062603 | Smith et al. | Nov 1991 | A |
5064413 | McKinnon et al. | Nov 1991 | A |
5071353 | van der Wal | Dec 1991 | A |
5085642 | Sarnoff et al. | Feb 1992 | A |
5092843 | Monroe et al. | Mar 1992 | A |
5104380 | Holman et al. | Apr 1992 | A |
5125898 | Kaufhold, Jr. et al. | Jun 1992 | A |
5167641 | Schmitz | Dec 1992 | A |
5199949 | Haber et al. | Apr 1993 | A |
5224936 | Gallagher | Jul 1993 | A |
5240146 | Smedley et al. | Aug 1993 | A |
5271527 | Haber et al. | Dec 1993 | A |
5279514 | Lacombe et al. | Jan 1994 | A |
5281198 | Haber et al. | Jan 1994 | A |
5286258 | Haber et al. | Feb 1994 | A |
5298023 | Haber et al. | Mar 1994 | A |
5312326 | Myers et al. | May 1994 | A |
5314406 | Arias et al. | May 1994 | A |
5314412 | Rex | May 1994 | A |
5314502 | McNichols et al. | May 1994 | A |
5343519 | Feldman | Aug 1994 | A |
5344407 | Ryan | Sep 1994 | A |
5354284 | Haber et al. | Oct 1994 | A |
5356376 | Milijasevic et al. | Oct 1994 | A |
5363842 | Mishelevich et al. | Nov 1994 | A |
5380281 | Tomellini et al. | Jan 1995 | A |
5383851 | McKinnon, Jr. et al. | Jan 1995 | A |
5383864 | van den Heuvel | Jan 1995 | A |
5394866 | Ritson et al. | Mar 1995 | A |
5399163 | Peterson et al. | Mar 1995 | A |
5399823 | McCusker | Mar 1995 | A |
5417660 | Martin | May 1995 | A |
5466217 | Myers et al. | Nov 1995 | A |
5505192 | Samiotes et al. | Apr 1996 | A |
5514135 | Earle | May 1996 | A |
5544647 | Jewett et al. | Aug 1996 | A |
5558679 | Tuttle | Sep 1996 | A |
5567160 | Massino | Oct 1996 | A |
5568555 | Shamir | Oct 1996 | A |
5569192 | van der Wal | Oct 1996 | A |
5584815 | Pawelka et al. | Dec 1996 | A |
5610992 | Hickman | Mar 1997 | A |
5615771 | Hollister | Apr 1997 | A |
5616132 | Newman | Apr 1997 | A |
5642731 | Kehr | Jul 1997 | A |
5645534 | Chanoch | Jul 1997 | A |
5662612 | Niehoff | Sep 1997 | A |
5681291 | Galli | Oct 1997 | A |
5692492 | Bruna et al. | Dec 1997 | A |
5695476 | Harris | Dec 1997 | A |
5697916 | Schraga | Dec 1997 | A |
5716338 | Hjertman et al. | Feb 1998 | A |
5728074 | Castellano et al. | Mar 1998 | A |
5740794 | Smith et al. | Apr 1998 | A |
5752235 | Kehr et al. | May 1998 | A |
5772635 | Dastur et al. | Jun 1998 | A |
5792190 | Olson et al. | Aug 1998 | A |
5800397 | Wilson et al. | Sep 1998 | A |
5805423 | Wever et al. | Sep 1998 | A |
5809997 | Wolf | Sep 1998 | A |
5813397 | Goodman et al. | Sep 1998 | A |
5814020 | Gross | Sep 1998 | A |
5823346 | Weiner | Oct 1998 | A |
5823363 | Cassel | Oct 1998 | A |
5832488 | Eberhardt | Nov 1998 | A |
5837546 | Allen et al. | Nov 1998 | A |
RE35986 | Ritson et al. | Dec 1998 | E |
5846089 | Weiss et al. | Dec 1998 | A |
5848988 | Davis | Dec 1998 | A |
5852590 | de la Huerga | Dec 1998 | A |
5853292 | Eggert et al. | Dec 1998 | A |
5868713 | Klippenstein | Feb 1999 | A |
5868721 | Marinacci | Feb 1999 | A |
D407487 | Greubel et al. | Mar 1999 | S |
5925021 | Castellano et al. | Jul 1999 | A |
5928195 | Malamud | Jul 1999 | A |
5941857 | Nguyen et al. | Aug 1999 | A |
5954641 | Kehr et al. | Sep 1999 | A |
5964739 | Champ | Oct 1999 | A |
5970457 | Brant et al. | Oct 1999 | A |
5971953 | Bachynsky | Oct 1999 | A |
5991655 | Gross et al. | Nov 1999 | A |
6002781 | Takayama et al. | Dec 1999 | A |
6015438 | Shaw | Jan 2000 | A |
6030363 | Kriesel | Feb 2000 | A |
6039713 | Botich et al. | Mar 2000 | A |
6045534 | Jacobsen et al. | Apr 2000 | A |
6062901 | Liu et al. | May 2000 | A |
6063053 | Castellano et al. | May 2000 | A |
6074213 | Hon | Jun 2000 | A |
6077106 | Mish | Jun 2000 | A |
6084526 | Blotky et al. | Jul 2000 | A |
6086562 | Jacobsen et al. | Jul 2000 | A |
6096002 | Landau | Aug 2000 | A |
6099503 | Stradella | Aug 2000 | A |
6099504 | Gross et al. | Aug 2000 | A |
6102896 | Roser | Aug 2000 | A |
6119684 | Nöhl et al. | Sep 2000 | A |
6144310 | Morris | Nov 2000 | A |
6149626 | Rachynsky et al. | Nov 2000 | A |
6158613 | Novosel et al. | Dec 2000 | A |
6161281 | Dando et al. | Dec 2000 | A |
6165155 | Jacobsen et al. | Dec 2000 | A |
6175752 | Say | Jan 2001 | B1 |
6179812 | Botich et al. | Jan 2001 | B1 |
6190326 | McKinnon et al. | Feb 2001 | B1 |
6192891 | Gravel et al. | Feb 2001 | B1 |
6193695 | Rippstein, Jr. | Feb 2001 | B1 |
6202642 | McKinnon et al. | Mar 2001 | B1 |
6210359 | Patel et al. | Apr 2001 | B1 |
6210369 | Wilmot et al. | Apr 2001 | B1 |
6219587 | Ahlin et al. | Apr 2001 | B1 |
6221045 | Duchon et al. | Apr 2001 | B1 |
6221055 | Shaw et al. | Apr 2001 | B1 |
6245046 | Sibbitt | Jun 2001 | B1 |
6249717 | Nicholson et al. | Jun 2001 | B1 |
6258063 | Haar et al. | Jul 2001 | B1 |
6259654 | de la Huerga | Jul 2001 | B1 |
6264629 | Landau | Jul 2001 | B1 |
6270455 | Brown | Aug 2001 | B1 |
6277098 | Klitmose et al. | Aug 2001 | B1 |
6285757 | Carroll et al. | Sep 2001 | B1 |
6312412 | Saied | Nov 2001 | B1 |
6317630 | Gross et al. | Nov 2001 | B1 |
6321070 | Clark et al. | Nov 2001 | B1 |
6321654 | Robinson | Nov 2001 | B1 |
6323780 | Morris | Nov 2001 | B1 |
6334070 | Nova et al. | Dec 2001 | B1 |
6357442 | Casper et al. | Mar 2002 | B1 |
6364866 | Furr et al. | Apr 2002 | B1 |
6371939 | Bergens et al. | Apr 2002 | B2 |
6377848 | Garde et al. | Apr 2002 | B1 |
6387078 | Gillespie, III | May 2002 | B1 |
6398760 | Danby | Jun 2002 | B1 |
6405912 | Giannou | Jun 2002 | B2 |
6411567 | Niemiec et al. | Jun 2002 | B1 |
6413236 | Van Dyke | Jul 2002 | B1 |
6425897 | Overes et al. | Jul 2002 | B2 |
6428517 | Hochman et al. | Aug 2002 | B1 |
6428528 | Sadowski | Aug 2002 | B2 |
6475181 | Potter et al. | Nov 2002 | B1 |
6478769 | Parker | Nov 2002 | B1 |
6478771 | Lavi et al. | Nov 2002 | B1 |
6482185 | Hartmann | Nov 2002 | B1 |
6494863 | Shaw et al. | Dec 2002 | B1 |
6500150 | Gross et al. | Dec 2002 | B1 |
6514230 | Munk et al. | Feb 2003 | B1 |
6529446 | de la Huerga | Mar 2003 | B1 |
6530900 | Daily et al. | Mar 2003 | B1 |
6530904 | Edwards et al. | Mar 2003 | B1 |
6535714 | Melker et al. | Mar 2003 | B2 |
6539281 | Wan et al. | Mar 2003 | B2 |
6540672 | Simonsen et al. | Apr 2003 | B1 |
6540675 | Aceti et al. | Apr 2003 | B2 |
6544234 | Gabriel | Apr 2003 | B1 |
6551276 | Mann et al. | Apr 2003 | B1 |
6551298 | Zhang | Apr 2003 | B1 |
6554798 | Mann et al. | Apr 2003 | B1 |
6558320 | Causey, III et al. | May 2003 | B1 |
6560471 | Heller | May 2003 | B1 |
6565533 | Smith et al. | May 2003 | B1 |
6569123 | Alchas | May 2003 | B2 |
6572584 | Shaw et al. | Jun 2003 | B1 |
6574166 | Niemiec | Jun 2003 | B2 |
6575939 | Brunel | Jun 2003 | B1 |
RE38189 | Walker et al. | Jul 2003 | E |
6585685 | Staylor et al. | Jul 2003 | B2 |
6585698 | Packman et al. | Jul 2003 | B1 |
6589158 | Winkler | Jul 2003 | B2 |
6589229 | Connelly | Jul 2003 | B1 |
6595956 | Gross et al. | Jul 2003 | B1 |
6597794 | Cole et al. | Jul 2003 | B2 |
6633796 | Pool et al. | Oct 2003 | B1 |
6641566 | Douglas et al. | Nov 2003 | B2 |
6645171 | Robinson et al. | Nov 2003 | B1 |
6645181 | Lavi et al. | Nov 2003 | B1 |
6659980 | Moberg et al. | Dec 2003 | B2 |
6676630 | Landau et al. | Jan 2004 | B2 |
6679862 | Diaz et al. | Jan 2004 | B2 |
6689093 | Landau | Feb 2004 | B2 |
6702778 | Hill et al. | Mar 2004 | B2 |
6707763 | Osberg et al. | Mar 2004 | B2 |
6708050 | Carim | Mar 2004 | B2 |
6722916 | Buccinna et al. | Apr 2004 | B2 |
6723077 | Pickup et al. | Apr 2004 | B2 |
6726661 | Munk et al. | Apr 2004 | B2 |
6736796 | Shekalim | May 2004 | B2 |
6743635 | Neel et al. | Jun 2004 | B2 |
6749437 | Chan | Jun 2004 | B2 |
6752781 | Landau et al. | Jun 2004 | B2 |
6767336 | Kaplan | Jul 2004 | B1 |
6770052 | Hill et al. | Aug 2004 | B2 |
6770056 | Price et al. | Aug 2004 | B2 |
6783509 | Landau et al. | Aug 2004 | B1 |
6786875 | Barker et al. | Sep 2004 | B2 |
6786885 | Hochman et al. | Sep 2004 | B2 |
6793646 | Giambattista et al. | Sep 2004 | B1 |
6803856 | Murphy et al. | Oct 2004 | B1 |
6805686 | Fathallah et al. | Oct 2004 | B1 |
6808514 | Schneider et al. | Oct 2004 | B2 |
6809653 | Mann et al. | Oct 2004 | B1 |
6817986 | Slate et al. | Nov 2004 | B2 |
6830560 | Gross et al. | Dec 2004 | B1 |
6839304 | Niemiec et al. | Jan 2005 | B2 |
6872200 | Mann et al. | Mar 2005 | B2 |
6875195 | Choi | Apr 2005 | B2 |
6883222 | Landau | Apr 2005 | B2 |
6923764 | Aceti et al. | Aug 2005 | B2 |
6936029 | Mann et al. | Aug 2005 | B2 |
6937150 | Medema et al. | Aug 2005 | B2 |
6942646 | Langley et al. | Sep 2005 | B2 |
6945961 | Miller et al. | Sep 2005 | B2 |
6946299 | Neel et al. | Sep 2005 | B2 |
6948492 | Wermeling et al. | Sep 2005 | B2 |
6949082 | Langley et al. | Sep 2005 | B2 |
6952604 | DeNuzzio et al. | Oct 2005 | B2 |
6953445 | Wilmot et al. | Oct 2005 | B2 |
6953693 | Neel et al. | Oct 2005 | B2 |
6958691 | Anderson et al. | Oct 2005 | B1 |
6959247 | Neel et al. | Oct 2005 | B2 |
6961285 | Niemiec et al. | Nov 2005 | B2 |
6963280 | Eskildsen | Nov 2005 | B2 |
6964650 | Alexandre et al. | Nov 2005 | B2 |
6969259 | Pastrick et al. | Nov 2005 | B2 |
6979316 | Rubin et al. | Dec 2005 | B1 |
6979326 | Mann et al. | Dec 2005 | B2 |
6985870 | Martucci et al. | Jan 2006 | B2 |
6997911 | Klitmose | Feb 2006 | B2 |
7014470 | Vann | Mar 2006 | B2 |
7072738 | Bonney et al. | Jul 2006 | B2 |
7074211 | Heiniger et al. | Jul 2006 | B1 |
7093595 | Nesbitt | Aug 2006 | B2 |
7104972 | Moller et al. | Sep 2006 | B2 |
7113101 | Peterson et al. | Sep 2006 | B2 |
7116233 | Zhurin | Oct 2006 | B2 |
7118553 | Scherer | Oct 2006 | B2 |
7126879 | Snyder | Oct 2006 | B2 |
7158011 | Brue | Jan 2007 | B2 |
7191916 | Clifford et al. | Mar 2007 | B2 |
7229458 | Boecker et al. | Jun 2007 | B2 |
7278983 | Ireland et al. | Oct 2007 | B2 |
7299981 | Hickle et al. | Nov 2007 | B2 |
7343914 | Abrams et al. | Mar 2008 | B2 |
7351223 | Call | Apr 2008 | B2 |
7416540 | Edwards et al. | Aug 2008 | B2 |
7544188 | Edwards et al. | Jun 2009 | B2 |
7648482 | Edwards et al. | Jan 2010 | B2 |
7648483 | Edwards et al. | Jan 2010 | B2 |
7682155 | Raven et al. | Mar 2010 | B2 |
7731686 | Edwards et al. | Jun 2010 | B2 |
7731690 | Edwards et al. | Jun 2010 | B2 |
7749194 | Edwards et al. | Jul 2010 | B2 |
7850662 | Veasey et al. | Dec 2010 | B2 |
7871393 | Monroe | Jan 2011 | B2 |
7918832 | Veasey et al. | Apr 2011 | B2 |
7938802 | Bicknell et al. | May 2011 | B2 |
7947017 | Edwards et al. | May 2011 | B2 |
8021344 | Edwards et al. | Sep 2011 | B2 |
8123719 | Edwards et al. | Feb 2012 | B2 |
8149111 | Monroe | Apr 2012 | B2 |
8172082 | Edwards et al. | May 2012 | B2 |
8206360 | Edwards et al. | Jun 2012 | B2 |
8212658 | Monroe | Jul 2012 | B2 |
8226610 | Edwards et al. | Jul 2012 | B2 |
8231573 | Edwards et al. | Jul 2012 | B2 |
8424517 | Sutherland et al. | Apr 2013 | B2 |
8544645 | Edwards et al. | Oct 2013 | B2 |
8556865 | Krulevitch et al. | Oct 2013 | B2 |
8556867 | Krulevitch et al. | Oct 2013 | B2 |
8622973 | Edwards et al. | Jan 2014 | B2 |
8690827 | Edwards et al. | Apr 2014 | B2 |
8899987 | Edwards et al. | Dec 2014 | B2 |
8920377 | Edwards et al. | Dec 2014 | B2 |
8926594 | Edwards et al. | Jan 2015 | B2 |
8932252 | Edwards et al. | Jan 2015 | B2 |
9022980 | Edwards et al. | May 2015 | B2 |
9056170 | Edwards et al. | Jun 2015 | B2 |
9084849 | Edwards et al. | Jul 2015 | B2 |
9149579 | Edwards et al. | Oct 2015 | B2 |
9173999 | Edwards et al. | Nov 2015 | B2 |
20010005781 | Bergens et al. | Jun 2001 | A1 |
20020000225 | Schuler et al. | Jan 2002 | A1 |
20020072784 | Sheppard, Jr. et al. | Jun 2002 | A1 |
20020074345 | Schneider et al. | Jun 2002 | A1 |
20020076679 | Aman | Jun 2002 | A1 |
20020090601 | Strupat et al. | Jul 2002 | A1 |
20020096543 | Juselius | Jul 2002 | A1 |
20020169439 | Flaherty | Nov 2002 | A1 |
20020183721 | Santini, Jr. et al. | Dec 2002 | A1 |
20020188419 | Slate | Dec 2002 | A1 |
20030028145 | Duchon et al. | Feb 2003 | A1 |
20030040717 | Saulenas et al. | Feb 2003 | A1 |
20030060765 | Campbell et al. | Mar 2003 | A1 |
20030065536 | Hansen | Apr 2003 | A1 |
20030106824 | Wilmot et al. | Jun 2003 | A1 |
20030120212 | Dedig et al. | Jun 2003 | A1 |
20030130853 | Maire | Jul 2003 | A1 |
20030132128 | Mazur | Jul 2003 | A1 |
20030233070 | De La Serna et al. | Dec 2003 | A1 |
20040019326 | Gilbert et al. | Jan 2004 | A1 |
20040039336 | Amark et al. | Feb 2004 | A1 |
20040039337 | Letzing | Feb 2004 | A1 |
20040039368 | Reilly et al. | Feb 2004 | A1 |
20040069667 | Tomellini et al. | Apr 2004 | A1 |
20040116854 | Abulhaj et al. | Jun 2004 | A1 |
20040138611 | Griffiths et al. | Jul 2004 | A1 |
20040143298 | Nova et al. | Jul 2004 | A1 |
20040159364 | Landau et al. | Aug 2004 | A1 |
20040210199 | Atterbury et al. | Oct 2004 | A1 |
20040220524 | Sadowski et al. | Nov 2004 | A1 |
20040225255 | Ono | Nov 2004 | A1 |
20040249358 | McWethy et al. | Dec 2004 | A1 |
20040267204 | Brustowicz | Dec 2004 | A1 |
20050027255 | Lavi et al. | Feb 2005 | A1 |
20050033234 | Sadowski et al. | Feb 2005 | A1 |
20050033386 | Osborn et al. | Feb 2005 | A1 |
20050055014 | Coppeta et al. | Mar 2005 | A1 |
20050062603 | Fuerst et al. | Mar 2005 | A1 |
20050088289 | Rochkind | Apr 2005 | A1 |
20050090781 | Baba et al. | Apr 2005 | A1 |
20050090782 | Marshall et al. | Apr 2005 | A1 |
20050133543 | Clifford et al. | Jun 2005 | A1 |
20050134433 | Sweeney, II | Jun 2005 | A1 |
20050137530 | Campbell et al. | Jun 2005 | A1 |
20050148931 | Juhasz | Jul 2005 | A1 |
20050148945 | Chen | Jul 2005 | A1 |
20050150488 | Dave | Jul 2005 | A1 |
20050159705 | Crawford et al. | Jul 2005 | A1 |
20050165360 | Stamp | Jul 2005 | A1 |
20050168337 | Mahoney | Aug 2005 | A1 |
20050171477 | Rubin et al. | Aug 2005 | A1 |
20050182358 | Veit et al. | Aug 2005 | A1 |
20050183982 | Giewercer | Aug 2005 | A1 |
20050186221 | Reynolds et al. | Aug 2005 | A1 |
20050190941 | Yang | Sep 2005 | A1 |
20050192530 | Castellano | Sep 2005 | A1 |
20050197654 | Edman et al. | Sep 2005 | A1 |
20050209558 | Marx | Sep 2005 | A1 |
20050209569 | Ishikawa et al. | Sep 2005 | A1 |
20050261742 | Nova et al. | Nov 2005 | A1 |
20050267403 | Landau et al. | Dec 2005 | A1 |
20050273059 | Mernoe et al. | Dec 2005 | A1 |
20050277891 | Sibbitt | Dec 2005 | A1 |
20060030819 | Young et al. | Feb 2006 | A1 |
20060053036 | Coffman et al. | Mar 2006 | A1 |
20060058848 | Piraino et al. | Mar 2006 | A1 |
20060074519 | Barker et al. | Apr 2006 | A1 |
20060089592 | Kadhiresan et al. | Apr 2006 | A1 |
20060106349 | Kito | May 2006 | A1 |
20060111666 | Hommann et al. | May 2006 | A1 |
20060111671 | Klippenstein | May 2006 | A1 |
20060116639 | Russell | Jun 2006 | A1 |
20060129090 | Moberg et al. | Jun 2006 | A1 |
20060189938 | Hommann et al. | Aug 2006 | A1 |
20060200077 | Righi et al. | Sep 2006 | A1 |
20060204939 | Bardsley et al. | Sep 2006 | A1 |
20060247578 | Arguendas et al. | Nov 2006 | A1 |
20060247579 | Friedman | Nov 2006 | A1 |
20060265186 | Holland et al. | Nov 2006 | A1 |
20070008113 | Spoonhower et al. | Jan 2007 | A1 |
20070074722 | Giroux et al. | Apr 2007 | A1 |
20070100288 | Bozeman et al. | May 2007 | A1 |
20070111175 | Raven et al. | May 2007 | A1 |
20070149954 | Hood et al. | Jun 2007 | A1 |
20070184847 | Hansen et al. | Aug 2007 | A1 |
20070186923 | Poutiatine et al. | Aug 2007 | A1 |
20070203247 | Phillips et al. | Aug 2007 | A1 |
20070210147 | Morrone et al. | Sep 2007 | A1 |
20070213598 | Howard et al. | Sep 2007 | A1 |
20070233001 | Burroughs et al. | Oct 2007 | A1 |
20070239116 | Follman et al. | Oct 2007 | A1 |
20070239140 | Chechelski et al. | Oct 2007 | A1 |
20070260210 | Conroy | Nov 2007 | A1 |
20070285238 | Batra | Dec 2007 | A1 |
20070285258 | Hartman | Dec 2007 | A1 |
20080111685 | Olson et al. | May 2008 | A1 |
20080160492 | Campbell et al. | Jul 2008 | A1 |
20080228143 | Stamp | Sep 2008 | A1 |
20080230057 | Sutherland | Sep 2008 | A1 |
20080234625 | Dacquay | Sep 2008 | A1 |
20090030285 | Andersen | Jan 2009 | A1 |
20090062728 | Woo | Mar 2009 | A1 |
20090131875 | Green | May 2009 | A1 |
20090143761 | Cantor et al. | Jun 2009 | A1 |
20090194104 | Van Sickle | Aug 2009 | A1 |
20090240200 | Heneveld et al. | Sep 2009 | A1 |
20100160894 | Julian et al. | Jun 2010 | A1 |
20100169111 | Brue et al. | Jul 2010 | A1 |
20100192948 | Sutherland et al. | Aug 2010 | A1 |
20100211005 | Edwards et al. | Aug 2010 | A1 |
20100214095 | Davide | Aug 2010 | A1 |
20100250280 | Sutherland | Sep 2010 | A1 |
20100250697 | Hansen | Sep 2010 | A1 |
20110077589 | Karlsson et al. | Mar 2011 | A1 |
20110144574 | Kamen et al. | Jun 2011 | A1 |
20110264033 | Jensen et al. | Oct 2011 | A1 |
20110295215 | Nielsen et al. | Dec 2011 | A1 |
20120015335 | Smith et al. | Jan 2012 | A1 |
20120046613 | Plumptre | Feb 2012 | A1 |
20120052837 | Reich et al. | Mar 2012 | A1 |
20120071819 | Bruggemann et al. | Mar 2012 | A1 |
20120079718 | Singer et al. | Apr 2012 | A1 |
20120101444 | Muller-Pathle et al. | Apr 2012 | A1 |
20120107783 | Julian et al. | May 2012 | A1 |
20120165747 | Lanin et al. | Jun 2012 | A1 |
20120233834 | Szechinski et al. | Sep 2012 | A1 |
20120238960 | Smith et al. | Sep 2012 | A1 |
20120253288 | Dasbach et al. | Oct 2012 | A1 |
20120259285 | Schabbach et al. | Oct 2012 | A1 |
20120271243 | Plumptre et al. | Oct 2012 | A1 |
20130079725 | Shang | Mar 2013 | A1 |
20130110050 | Boyd et al. | May 2013 | A1 |
20130184649 | Edwards et al. | Jul 2013 | A1 |
20130190692 | Edwards et al. | Jul 2013 | A1 |
20130266919 | Baker et al. | Oct 2013 | A1 |
20140276385 | Baker et al. | Sep 2014 | A1 |
20140296824 | Edwards et al. | Oct 2014 | A1 |
20140371714 | Edwards et al. | Dec 2014 | A1 |
20150011973 | Edwards et al. | Jan 2015 | A1 |
20150190591 | Edwards et al. | Jul 2015 | A1 |
20150196711 | Edwards et al. | Jul 2015 | A1 |
20160166768 | Edwards et al. | Jun 2016 | A1 |
20160184535 | Edwards et al. | Jun 2016 | A1 |
20160235916 | Edwards et al. | Aug 2016 | A1 |
20170049954 | Edwards et al. | Feb 2017 | A1 |
20170092101 | Edwards et al. | Mar 2017 | A1 |
20170312433 | Edwards et al. | Nov 2017 | A1 |
20180102066 | Edwards | Apr 2018 | A1 |
Number | Date | Country |
---|---|---|
2004231230 | Jun 2006 | AU |
1043037 | Oct 2000 | EP |
1113700 | Jul 2001 | EP |
1287840 | Mar 2003 | EP |
1462134 | Sep 2004 | EP |
1518575 | Mar 2005 | EP |
1712178 | Oct 2006 | EP |
1777984 | Apr 2007 | EP |
1883268 | Jan 2008 | EP |
2195544 | Apr 1988 | GB |
H08507239 | Aug 1996 | JP |
2006-034845 | Feb 2006 | JP |
WO 9104760 | Apr 1991 | WO |
WO 9302720 | Feb 1993 | WO |
WO 9526009 | Sep 1995 | WO |
WO 9625965 | Aug 1996 | WO |
WO 9730742 | Aug 1997 | WO |
WO 9852632 | Nov 1998 | WO |
WO 9907425 | Feb 1999 | WO |
WO 9910031 | Mar 1999 | WO |
WO 9943283 | Sep 1999 | WO |
WO 2001024690 | Apr 2001 | WO |
WO 2001026020 | Apr 2001 | WO |
WO 2001041849 | Jun 2001 | WO |
WO 2001088828 | Nov 2001 | WO |
WO 2001093926 | Dec 2001 | WO |
WO 2002024257 | Mar 2002 | WO |
WO 2003057283 | Jul 2003 | WO |
WO 03057286 | Jul 2003 | WO |
WO 2003095001 | Nov 2003 | WO |
WO 2003097133 | Nov 2003 | WO |
WO 2004041330 | May 2004 | WO |
WO 2005050526 | Jun 2005 | WO |
WO 2005077441 | Aug 2005 | WO |
WO 2006045525 | May 2006 | WO |
WO 2006085175 | Aug 2006 | WO |
WO 2006085204 | Aug 2006 | WO |
WO 2006109778 | Oct 2006 | WO |
WO 2006123956 | Nov 2006 | WO |
WO 2006125692 | Nov 2006 | WO |
WO 2007083115 | Jul 2007 | WO |
WO 2007087304 | Aug 2007 | WO |
WO 2007088444 | Aug 2007 | WO |
WO 2008005315 | Jan 2008 | WO |
WO 2008148864 | Dec 2008 | WO |
WO 2010114392 | Oct 2010 | WO |
WO 2013043063 | Mar 2013 | WO |
WO 2013044172 | Mar 2013 | WO |
WO 2008008451 | Jan 2018 | WO |
Entry |
---|
Office Action for Canadian Patent Application No. 2,762,072, dated Mar. 14, 2016. |
“Solutions for Medical Devices,” 3M Brochure, © 3M, (2006), 80-6201-3490-0, 8 pages. |
Tingelstad, M., “Revolutionary Medical Technology Increases Demand for Flexible Interconnects,” [online] May 15, 2006 [retrieved on Nov. 15, 2006] Retrieved from the Internet <URL: http://www.ecnmag.com/index.asp?layout=articlePrint&ArticleID=CA6332947>, 3 pages. |
“Flexible circuits / Flex circuits / Flexible Technology Ltd.,” Flexible Technology Limited [online] [retrieved on Aug. 28, 2006] Retrieved from the Internet <URL: http://www.flexibletechnology.com/ >, 2 pages. |
“Flexible circuits capabilities of Flexible Technology Limited,” Our Flexible Circuits Capabilities [online] [retrieved on Aug. 28, 2006] Retrieved from the Internet <URL: http://www.flexibletechnology.com/Flexible circuits Capability.htm >, 2 pages. |
“Flex Circuits/flexible circuits design guide,” [online] [retrieved on Aug. 28, 2006] Retrieved from the Internet <URL: http://flexiblecircuit.co.uk/Flex Circuits Design Guide.htm >, 7 pages. |
“Insect Stings Auto-injector Pouches and Carry Cases,” The Insect Stings On-Line Shop, [online] [retrieved on Jan. 24, 2007] Retrieved from the Internet <URL: http://www.insectstings.co.uk/acatalog/Auto Injector Pouches.html>, 3 pages. |
“Anaphylaxis Canada Product Catalogue,” Anaphylaxis Canada > Living with Anaphylaxis > Tools and Resources [online] [retrieved on 1/24/07] Retrieved from the Internet <URL: http://anaphylaxis.org/content/livingwith/product catalogue.asp >, 9 pages. |
“Microfluidics Device Provides Programmed, Long-Term Drug Dosing,” nano techwire.com [online] [retrieved on Nov. 28, 2006] Retrieved from the Internet <URL: http://nanotechwire.com/news.asp?nid=3141&ntid=124&pg=1>, 3 pages. |
Allan, R., “Medical Electronics: Technology Advances Will Revolutionize Healthcare,” Sep. 30, 2002 [online] [retrieved on Nov. 28, 2006] Retrieved from the Internet <URL: http://www.elecdesign.com/Articles/Index.cfm?AD=1&ArticleID=2041>, 3 pages. |
RFID Gazette, “Smart Labels in Healthcare,” Sep. 29, 2005 [online] [retrieved on Nov. 28, 2006] Retrieved from the Internet <URL: http://www.rfidagazeete.org/2005/09/smart labels in.html >, 2 pages. |
“Merck Serono Launches easypod(R), First Electronic Growth Hormone Injection Device,” Jan. 30, 2007 [online] [retrieved on Feb. 5, 2007] Retrieved from the Internet <URL: http://www.biz.yahoo.com/prnews/070130/ukm028.html?.v=8>, 3 pages. |
Scholz, O., “Drug depot in a tooth,” [online] [retrieved on Feb. 6, 2007] Retrieved from the Internet <URL: http://www.fraunhoferde/fhg/EN/press/pi/2007/02Mediendienst22007Thema2.jsp?print=true>, 1 page. |
Heartsine Technology, samaritan™ Pad Accessories [online] [retrieved on Jun. 1, 2007] Retrieved from the Internet <URL: http://www.heartsine.com/aboutsam-accessories.htm>, 4 pages. |
CliniSense Corporation, “Drug delivery devices A potentially harsh environment for drugs,” Stability [online] [retrieved on Jun. 1, 2007] Retrieved from the Internet <URL: http://www.clinisense.com/devices.htm>, 2 pages. |
CliniSense Corporation, “LifeTrack Technology a new method to detect improper storage.” Stability [online] [retrieved on Jun. 1, 2007] Retrieved from the Internet <URL: http://www.clinisense.com/tech.htm>, 2 pages. |
AED Professionals™ Brochure [online] [retrieved on Jun. 1, 2007] Retrieved from the Internet <URL: http://www.aedprofessionals.com>, 4 pages. |
Ruppar, D., “Implant Technologies Expected to Remain a Niche but Effective Method of Drug Delivery,” Drug Delivery Technology, Feb. 2007, vol. 7, No. 2 [online] [retrieved on Jun. 1, 2007] Retrieved from the Internet <URL: http://www.drugdeliverytech-online.com/drugdelivery/200702/templates/pageviewer_print?pg=44&pm=8 >, 8 pages. |
Meridian Medical Technologies, Inc., “Pralidoxime Chloride Trainer,” 2006. [retrieved on Feb. 16, 2007] Retrieved from the Internet <URL: http://www.meridianmeds.com/auto-injectors/2pamcl_trainer.html/>, 1 pages. |
Gosbee, L. L., “Nuts! I Can't Figure Out How to Use My Life-Saving Epinephrine Auto-Injector,” Joint Commision Journal on Quality and Safety, 30(4):220-223 (Apr. 2004). |
Amgen, “Using Aranesp prefilled SureClick autoinjector is a simple 3-step process,” 2006. [retrieved on Feb. 16, 2007] Retrieved from the Internet <URL: http://www.aranesp.com/patient/cia/sureclick/using_three_steps.jsp/>, 4 pages. |
Office Action for Israel Patent Application No. 184552, dated Jul. 28, 2011. |
International Search Report and Written Opinion for International Patent Application No. PCT/US06/03415, dated Jul. 13, 2006, 10 pages. |
Search Report for European Patent Application No. 09150135.3, dated Mar. 15, 2010. |
Office Action for European Patent Application No. 09150135.3, dated Jul. 11, 2011. |
Combined Search and Examination Report for British Patent Application 0818178.6, dated Dec. 1, 2008. |
Examination Report for British Patent Application No. 0818178.6, dated Mar. 23, 2009. |
Examination Report for British Patent Application No. 0818178.6, dated Jul. 9, 2009. |
Examination Report for British Patent Application No. 0905194.7, dated May 8, 2009. |
Office Action for Canadian Patent Application No. 2,644,547, dated Feb. 14, 2014. |
Office Action for Japanese Patent Application No. 2009-502964, dated May 23, 2011. |
Office Action for Japanese Patent Application No. 2009-502964, dated May 21, 2012 (English Translation). |
International Search Report and Written Opinion for International Patent Application No. PCT/US07/007626, dated Sep. 29, 2008. |
Search and Examination Report for British Patent Application No. 1104754.5, dated May 18, 2011. |
Office Action for U.S. Appl. No. 11/621,236, dated Feb. 3, 2009. |
Office Action for U.S. Appl. No. 11/621,236, dated Jul. 1, 2009. |
Search and Examination Report for British Patent Application No. 1108993.5, dated Jun. 17, 2011. |
Office Action for U.S. Appl. No. 11/671,025, dated Mar. 24, 2011. |
Office Action for U.S. Appl. No. 11/671,025, dated Sep. 8, 2011. |
Office Action for U.S. Appl. No. 11/679,331, dated Feb. 15, 2011. |
Office Action for U.S. Appl. No. 11/679,331, dated May 12, 2010. |
English Translation of Office Action for Chinese Patent Application No. 200980124254.1, dated Oct. 30, 2012. |
Examination Report for British Patent Application No. 1019599.8, dated Feb. 7, 2012. |
Office Action for U.S. Appl. No. 12/119,016, dated Nov. 3, 2011. |
International Preliminary Report on Patentability for International Patent Application No. PCT/US2009/043578, dated Nov. 17, 2010. |
Office Action for U.S. Appl. No. 12/794,020, dated Oct. 25, 2011. |
Office Action for U.S. Appl. No. 13/404,699, dated Mar. 10, 2014. |
Non-Final Office Action for U.S. Appl. No. 13/550,893, dated Aug. 15, 2014. |
Office Action for U.S. Appl. No. 13/550,893, dated Apr. 28, 2015. |
Office Action for U.S. Appl. No. 13/924,037, dated Feb. 13, 2014. |
Office Action for U.S. Appl. No. 13/962,336, dated Nov. 20, 2013. |
Office Action for U.S. Appl. No. 13/962,336, dated May 27, 2014. |
Office Action for U.S. Appl. No. 12/180,708, dated Feb. 28, 2011. |
Office Action for U.S. Appl. No. 12/615,636, dated Jan. 25, 2012. |
International Search Report and Written Opinion for International Patent Application No. PCT/US09/63983, dated Feb. 25, 2010. |
International Search Report and Written Opinion for International Application No. PCT/US2012/022675, dated May 25, 2012. |
Knapp, Louise. “A Faster Way to Call 911,” Wired.com [online], [retrieved Jul. 26, 2017] Retrieved from the Internet <https://www.wired.com/2001/03/a-faster-way-to-call-911> (Mar. 10, 2001), 9 pages. |
Office Action for Canadian Patent Application No. 2,724,069, dated Jan. 25, 2017. |
Office Action for U.S. Appl. No. 14/142,287, dated Apr. 6, 2017. |
Office Action for U.S. Appl. No. 14/148,268 dated Jun. 15, 2017. |
Office Action for Australia Patent Application No. 2015249064, dated Aug. 25, 2017. |
Office Action for U.S. Appl. No. 15/061,462, dated Oct. 10, 2017. |
Office Action for U.S. Appl. No. 15/139,826, dated Dec. 4, 2017. |
Extended European Search Report for European Patent Application No. 07754184.5, dated Feb. 2, 2018. |
Office Action for U.S. Appl. No. 15/061,462, dated Feb. 28, 2018. |
Number | Date | Country | |
---|---|---|---|
20160121056 A1 | May 2016 | US |
Number | Date | Country | |
---|---|---|---|
60648822 | Feb 2005 | US | |
60731886 | Oct 2005 | US | |
60787046 | Mar 2006 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 13550893 | Jul 2012 | US |
Child | 14993234 | US | |
Parent | 12119016 | May 2008 | US |
Child | 13550893 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 11679331 | Feb 2007 | US |
Child | 12119016 | US | |
Parent | 11671025 | Feb 2007 | US |
Child | 11679331 | US | |
Parent | 11621236 | Jan 2007 | US |
Child | 11671025 | US | |
Parent | 10572148 | US | |
Child | 11621236 | US |